Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | XIAP | P98170 | 11/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3612495 | 0.91 | XIAP (0.50) | MEN1KMT2AXIAPF11 | |
| SCHEMBL3612848 | 0.83 | XIAP (0.47) | MEN1KMT2AXIAPLMNANPC1 | |
| SCHEMBL3609162 | 0.82 | KMT2A (0.47) | MEN1KMT2AXIAPLMNANPC1 | |
| SCHEMBL3598720 | 0.81 | XIAP (0.45) | MEN1KMT2AXIAPF11 | |
| SCHEMBL3607633 | 0.81 | XIAP (0.53) | MEN1KMT2AXIAPF11 | |
| SCHEMBL3606637 | 0.80 | MEN1 (0.50) | MEN1KMT2ALMNA | |
| SCHEMBL3613913 | 0.79 | KMT2A (0.42) | MEN1KMT2AXIAPLMNANPC1 | |
| SCHEMBL3613507 | 0.78 | XIAP (0.43) | MEN1KMT2AXIAPF11 | |
| SCHEMBL3617454 | 0.78 | XIAP (0.43) | MEN1KMT2AXIAPNPC1F11 | |
| SCHEMBL3609009 | 0.77 | XIAP (0.42) | MEN1KMT2AXIAPNPC1F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2010-01-28 | — | — | US | disclosed |
| EP-1857444-A1 | TETRAHYDROISOQUINOLINE COMPOUND AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022582-A1 | Tetrahydroisoquinoline Compound and Medicinal Use Thereof | ACAT1, ACAT2, LCAT | MEN1 4401/4885KMT2A 343/4885XIAP 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.